Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aurora Biosciences (ABSC) -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (237)	12/16/1999 8:13:00 PM
From: Larry Liebman	Read Replies (1) \| Respond to of 359

5 year deal with Wyeth for ion channel research announced today...following a similar Glaxo release yesterday. Added more at $11 1/2- dawdled at 10 7/8, missing the opportunity. Market cap of $200 million+. Would do some DD by visiting website. ABSC reminds me of MLNM in the sheer volume of agreements with big pharma...except, it appears it will be in the black this year. In addition, release by company has their proprietary UHTSS unit operating early in first quarter '00, with ABSC comment it will increase their internal screening capacity by a factor of 10. Am I missing something with stock at $11 7/8?